Barclays’s RenovoRx RNXT Stock Holding History

Barclays’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,151	Closed	-$1.13K	–	5674
2026 Q2	$1.13K	Buy	+1,151	New	+$1.05K	﹤0.01%	4919
2025 Q4	–	Sell	-118	Closed	-$150	–	5608
2025 Q3	$150	Buy	+118	New	+$140	﹤0.01%	5256
2025 Q2	–	Sell	-43	Closed	-$43	–	5493
2025 Q1	$43	Buy	+43	New	+$50	﹤0.01%	5151

Other funds holding RNXT

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

T3 Companies New York $103M AUM 54.73% 1-Year Est. Return

Chicago Partners Investment Group Chicago, Illinois $5.45B AUM 19.52% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return

Clear Creek Financial Management Silverdale, Washington $1.33B AUM 22.52% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Affinity Capital Advisors Berkeley, California $856M AUM 17.43% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Barclays's RNXT Position: Q3 2026 in Review

Barclays sold out of RenovoRx (RNXT) in Q3 2026, closing a stake of 1,151 shares — an estimated $1.13K sold.

Barclays first reported a position in RNXT in Q1 2025 and held it in 3 quarters. The position peaked at $1.13K in Q2 2026. 9 funds tracked by Wall St. Rank hold RNXT as of Q3 2026.

Barclays reported no remaining RenovoRx position as of Q3 2026 after selling out during the quarter.
Barclays sold 1,151 RenovoRx shares in Q3 2026, an estimated $1.13K.
Barclays first reported a position in RenovoRx in Q1 2025 and held it in 3 quarters.
Barclays's RenovoRx position peaked at $1.13K in Q2 2026.
9 funds tracked by Wall St. Rank held RenovoRx as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.